Skip to main content

Macular Degeneration clinical trials at UCSF
4 in progress, 1 open to eligible people

  • Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

    open to eligible people ages 55 years and up

    The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).

    San Francisco, California and other locations

  • A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

    Sorry, in progress, not accepting new patients

    A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.

    San Diego, California and other locations

  • A Phase III Study to Evaluate the Port Delivery System Implant With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)

    Sorry, in progress, not accepting new patients

    Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port Delivery System (PDS) compared with ranibizumab intravitreal injections at 0.5 mg (10 mg/mL) in participants with neovascular age-related macular degeneration (nAMD).

    San Francisco, California and other locations

  • Extension Study for the Port Delivery System With Ranibizumab (Portal)

    Sorry, not currently recruiting here

    This study will evaluate the long-term safety and tolerability of the Port Delivery System (PDS) with ranibizumab 100 mg/mL with refills administered every 24 weeks (Q24W) for approximately 144 weeks in participants with neovascular age-related macular degeneration (nAMD) who have completed either Phase II Study GX28228 (Ladder) or Phase III Study GR40548 (Archway).

    San Francisco, California and other locations

Last updated: